Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol Source: Eur Respir J 2016; 48: 320-330 Year: 2016
Phase three studies of biologics for severe asthma: could do better? Source: Eur Respir J, 50 (3) 1701108; 10.1183/13993003.01108-2017 Year: 2017
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT) Source: International Congress 2017 – Many faces of asthma assessment Year: 2017
Latent classes of adults with persistent asthma: data from the multicentre INSPIRERS studies Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Augmentation therapy for α1 -antitrypsin deficiency: a meta-analysis of randomized and non-randomized clinical studies Source: Eur Respir J 2005; 26: Suppl. 49, 288s Year: 2005
Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Smoking cessation interventions in COPD: a network meta-analysis of randomised trials Source: Eur Respir J 2009; 34: 634 Year: 2009
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Evidence generation for the clinical impact of myCOPD in patients with mild, moderate and newly diagnosed COPD: a randomised controlled trial Source: ERJ Open Res, 6 (4) 00460-2020; 10.1183/23120541.00460-2020 Year: 2020
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Risankizumab in severe asthma: A Phase IIa, placebo-controlled study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020